echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Hengrui shr7390 tablet and Baiji Shenzhou bgb-3111 capsule were approved for clinical use

    Hengrui shr7390 tablet and Baiji Shenzhou bgb-3111 capsule were approved for clinical use

    • Last Update: 2020-04-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The clinical application of class 1.1 new drugs of shr7390 tablets entered CFDA drug review center on December 31, 2014, and took a special review channel

    Shr7390 is a MEK kinase inhibitor developed for cancer

    Last week, Hengrui just got 6 clinical approvals

    On February 13, 2015, the clinical application of class 1.1 new drug of bgb-3111 capsule entered the CFDA drug review center and took a special review channel

    Bgb-3111 is a Btk inhibitor, which is said to have higher selectivity than ibrutinib, the world's first btik inhibitor

    The preliminary results of the phase I study of bgb-3111 single drug in the treatment of multiple advanced B-cell malignancies were announced at the ash2015 annual meeting of Baiji Shenzhou on December 7.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.
    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent Echemi's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.